- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05021055
Multicentric Study for External Validation of a Deep Learning Model for Mammographic Breast Density Categorization
19. August 2021 aktualisiert von: Hospital Italiano de Buenos Aires
The correct categorization of breast density is essential to adapt the diagnostic examination to the needs of each patient.
Assessment of breast density is performed visually by radiologists.
Some authors have detected that this method involves considerable intra and interobserver variability.
On the other hand, automated systems for measuring breast density are becoming more and more frequent.
Machine learning is a domain of Artificial Intelligence, which comprises the process of developing systems with the ability to learn and make predictions using data.
These systems are designed to aid healthcare professional decision making.
In the present work, the multicenter study of external validation of a tool based on deep learning for the categorization of mammographic breast density is proposed.
Studienübersicht
Status
Noch keine Rekrutierung
Bedingungen
Detaillierte Beschreibung
The correct categorization of breast density is essential to adapt the diagnostic examination to the needs of each patient.
Assessment of breast density is performed visually by radiologists.
Some authors have detected that this method involves considerable intra and interobserver variability.
On the other hand, automated systems for measuring breast density are becoming more and more frequent.
Consequently, in clinical practice, breast density is reported from the assessment carried out by specialists with the support of these systems.
But there are few studies about the use, concordance and perception of usefulness of professionals on these tools.
A study carried out at the Hospital Italiano de Buenos Aires reported a moderate to almost perfect inter- and intra-observer agreement among radiologists and a moderate concordance between the categorization carried out by experts and that carried out by commercial software of a digital mammography machine.
Machine learning is a domain of Artificial Intelligence, which comprises the process of developing systems with the ability to learn and make predictions using data.
Once a system designed to aid healthcare professional decision making is developed, it must be validated.
In 2019, an internal validation of a tool based on deep learning techniques was carried out for the automatic categorization of mammographic breast density.
The tool reached a very good interobserver agreement, kappa = 0.64 (95% CI 0.58-0.69),
when compared with the performance of the professionals.
It reached a sensitivity of 83.2 (CI: 76.9-88.3)
and a specificity of 88.4 (83.9-92.0.)
In the present work, the multicenter study of external validation of a tool based on deep learning for the categorization of mammographic breast density is proposed.
The evaluation of this tool will be carried out in two external institutions: Hospital Alemán and Fundación Científica del Sur.
Studientyp
Beobachtungs
Einschreibung (Voraussichtlich)
277
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienkontakt
- Name: Andrés Brandan
- Telefonnummer: +5493816212804
- E-Mail: andres.brandan@hospitalitaliano.org.ar
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
- Kind
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Ja
Studienberechtigte Geschlechter
Alle
Probenahmeverfahren
Nicht-Wahrscheinlichkeitsprobe
Studienpopulation
The unit of analysis will be the bilateral mammographic images with mediolateral oblique and craniocaudal views.
The images selected for this study will be screening mammograms performed at Saint John's Cancer Institute.
The institution will select the images according to the inclusion and exclusion criteria.
The images will be extracted from the institutional database retrospectively and will be anonymized without any personal data, except for the age of the patient.
These images will be stored in DICOM format, in a safe place with restricted access limited only to the investigation team.
Beschreibung
Inclusion Criteria:
Mammograms included in the study should meet the following criteria:
- Female patients of 40 years of age or more.
- To have at least one screening mammography exam performed at Saint John's
- Cancer Institute during the study period. These exams will be included regardless of the brand of the mammography equipment.
- Mammograms should be performed with digital equipment.
Exclusion Criteria:
Mammograms with the following criteria will be excluded from the study:
- Patients with gigantomastia, defined by the need for more than one image of each mammographic view (mediolateral oblique and craniocaudal) to evaluate the entire breast volume.
- Patients with breast implants.
- Patients with a history of breast surgery.
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Agreement between the majority report and Artemisia´s categorization of dense breasts/non-dense breasts
Zeitfenster: 2 months
|
The agreement between the CNN and the total of the professionals' categorizations will be calculated with the linear weighted kappa.
To this end, the categories assigned by the professionals will be considered as only one observer in each one of the studies and they will be compared to those assigned by Artemisia for the same set of images.
|
2 months
|
Agreement between the majority report and Artemisia in each one of the four breast density categories
Zeitfenster: 2 months
|
For each one of the professionals involved in the study, the agreement with the CNN will be calculated with the linear weighted kappa coefficient.
To this end, the categories assigned by the professionals will be considered as only one observer in each one of the studies and they will be compared to those assigned by Artemisia for the same set of images.
|
2 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Agreement between each observer and Artemisia´s categorization of dense breasts/non-dense breasts
Zeitfenster: 2 months
|
To this end, the categories assigned by the professionals will be considered as only one observer in each one of the studies and they will be compared to those assigned by Artemisia for the same set of images.
|
2 months
|
Agreement between each observer and Artemisia in each one of the four breast density categories
Zeitfenster: 2 months
|
For each one of the professionals involved in the study, the agreement with the CNN will be calculated with the linear weighted kappa coefficient.
To this end, the categories assigned by the professionals will be considered as only one observer in each one of the studies and they will be compared to those assigned by Artemisia for the same set of images.
|
2 months
|
Agreement between each observer and the majority report in the categorization of dense breasts/non-dense breasts
Zeitfenster: 2 months
|
For each one of the professionals involved in the study, the agreement with the majority report will be calculated with the linear weighted kappa coefficient.
To this end, the categories assigned by the professionals will be considered as only one observer in each one of the studies and they will be compared to those assigned by the majority report for the same set of images.
|
2 months
|
Agreement between each observer and the majority report in each one of the four breast density categories
Zeitfenster: 2 months
|
For each one of the professionals involved in the study, the agreement with the majority report will be calculated with the linear weighted kappa coefficient.
To this end, the categories assigned by the professionals will be considered as only one observer in each one of the studies and they will be compared to those assigned by the majority report for the same set of images.
|
2 months
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Ermittler
- Hauptermittler: Daniel R Luna, MD, Hospital Italiano de Buenos Aires
Publikationen und hilfreiche Links
Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.
Allgemeine Veröffentlichungen
- Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, Jong RA, Hislop G, Chiarelli A, Minkin S, Yaffe MJ. Mammographic density and the risk and detection of breast cancer. N Engl J Med. 2007 Jan 18;356(3):227-36. doi: 10.1056/NEJMoa062790.
- Winkler NS, Raza S, Mackesy M, Birdwell RL. Breast density: clinical implications and assessment methods. Radiographics. 2015 Mar-Apr;35(2):316-24. doi: 10.1148/rg.352140134.
- Ciatto S, Visioli C, Paci E, Zappa M. Breast density as a determinant of interval cancer at mammographic screening. Br J Cancer. 2004 Jan 26;90(2):393-6. doi: 10.1038/sj.bjc.6601548.
- Wanders JOP, Holland K, Karssemeijer N, Peeters PHM, Veldhuis WB, Mann RM, van Gils CH. The effect of volumetric breast density on the risk of screen-detected and interval breast cancers: a cohort study. Breast Cancer Res. 2017 Jun 5;19(1):67. doi: 10.1186/s13058-017-0859-9.
- Strand F, Azavedo E, Hellgren R, Humphreys K, Eriksson M, Shepherd J, Hall P, Czene K. Localized mammographic density is associated with interval cancer and large breast cancer: a nested case-control study. Breast Cancer Res. 2019 Jan 22;21(1):8. doi: 10.1186/s13058-019-1099-y.
- Swann CA, Kopans DB, McCarthy KA, White G, Hall DA. Mammographic density and physical assessment of the breast. AJR Am J Roentgenol. 1987 Mar;148(3):525-6. doi: 10.2214/ajr.148.3.525.
- A L Mousa DS, Ryan EA, Mello-Thoms C, Brennan PC. What effect does mammographic breast density have on lesion detection in digital mammography? Clin Radiol. 2014 Apr;69(4):333-41. doi: 10.1016/j.crad.2013.11.014. Epub 2014 Jan 11.
- Carreira Gomez MC, Estrada Blan MC. What we need to know about dense breasts: implications for breast cancer screening. Radiologia. 2016 Nov-Dec;58(6):421-426. doi: 10.1016/j.rx.2016.08.002. Epub 2016 Oct 15. English, Spanish.
- McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1159-69. doi: 10.1158/1055-9965.EPI-06-0034.
- Sprague BL, Conant EF, Onega T, Garcia MP, Beaber EF, Herschorn SD, Lehman CD, Tosteson AN, Lacson R, Schnall MD, Kontos D, Haas JS, Weaver DL, Barlow WE; PROSPR Consortium. Variation in Mammographic Breast Density Assessments Among Radiologists in Clinical Practice: A Multicenter Observational Study. Ann Intern Med. 2016 Oct 4;165(7):457-464. doi: 10.7326/M15-2934. Epub 2016 Jul 19.
- Eom HJ, Cha JH, Kang JW, Choi WJ, Kim HJ, Go E. Comparison of variability in breast density assessment by BI-RADS category according to the level of experience. Acta Radiol. 2018 May;59(5):527-532. doi: 10.1177/0284185117725369. Epub 2017 Aug 2.
- Alikhassi A, Esmaili Gourabi H, Baikpour M. Comparison of inter- and intra-observer variability of breast density assessments using the fourth and fifth editions of Breast Imaging Reporting and Data System. Eur J Radiol Open. 2018 Apr 20;5:67-72. doi: 10.1016/j.ejro.2018.04.002. eCollection 2018.
- Melnikow J, Fenton JJ, Whitlock EP, Miglioretti DL, Weyrich MS, Thompson JH, Shah K. Supplemental Screening for Breast Cancer in Women With Dense Breasts: A Systematic Review for the U.S. Preventive Services Task Force. Ann Intern Med. 2016 Feb 16;164(4):268-78. doi: 10.7326/M15-1789. Epub 2016 Jan 12.
- Jeffers AM, Sieh W, Lipson JA, Rothstein JH, McGuire V, Whittemore AS, Rubin DL. Breast Cancer Risk and Mammographic Density Assessed with Semiautomated and Fully Automated Methods and BI-RADS. Radiology. 2017 Feb;282(2):348-355. doi: 10.1148/radiol.2016152062. Epub 2016 Sep 5.
- Ciatto S, Bernardi D, Calabrese M, Durando M, Gentilini MA, Mariscotti G, Monetti F, Moriconi E, Pesce B, Roselli A, Stevanin C, Tapparelli M, Houssami N. A first evaluation of breast radiological density assessment by QUANTRA software as compared to visual classification. Breast. 2012 Aug;21(4):503-6. doi: 10.1016/j.breast.2012.01.005. Epub 2012 Jan 27.
- Alonzo-Proulx O, Jong RA, Yaffe MJ. Volumetric breast density characteristics as determined from digital mammograms. Phys Med Biol. 2012 Nov 21;57(22):7443-57. doi: 10.1088/0031-9155/57/22/7443. Epub 2012 Oct 24.
- Martinez Gomez I, Casals El Busto M, Anton Guirao J, Ruiz Perales F, Llobet Azpitarte R. Semiautomatic estimation of breast density with DM-Scan software. Radiologia. 2014 Sep-Oct;56(5):429-34. doi: 10.1016/j.rx.2012.11.007. Epub 2013 Mar 13. English, Spanish.
- Gao J, Warren R, Warren-Forward H, Forbes JF. Reproducibility of visual assessment on mammographic density. Breast Cancer Res Treat. 2008 Mar;108(1):121-7. doi: 10.1007/s10549-007-9581-0. Epub 2007 Jul 7.
- Pesce K, Tajerian M, Chico MJ, Swiecicki MP, Boietti B, Frangella MJ, Benitez S. Interobserver and intraobserver variability in determining breast density according to the fifth edition of the BI-RADS(R) Atlas. Radiologia (Engl Ed). 2020 Nov-Dec;62(6):481-486. doi: 10.1016/j.rx.2020.04.006. Epub 2020 May 31. English, Spanish.
- Do S, Song KD, Chung JW. Basics of Deep Learning: A Radiologist's Guide to Understanding Published Radiology Articles on Deep Learning. Korean J Radiol. 2020 Jan;21(1):33-41. doi: 10.3348/kjr.2019.0312.
- Liu Y, Chen PC, Krause J, Peng L. How to Read Articles That Use Machine Learning: Users' Guides to the Medical Literature. JAMA. 2019 Nov 12;322(18):1806-1816. doi: 10.1001/jama.2019.16489.
- Dontchos BN, Yala A, Barzilay R, Xiang J, Lehman CD. External Validation of a Deep Learning Model for Predicting Mammographic Breast Density in Routine Clinical Practice. Acad Radiol. 2021 Apr;28(4):475-480. doi: 10.1016/j.acra.2019.12.012. Epub 2020 Feb 20.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Voraussichtlich)
1. September 2021
Primärer Abschluss (Voraussichtlich)
1. April 2022
Studienabschluss (Voraussichtlich)
1. Juli 2022
Studienanmeldedaten
Zuerst eingereicht
19. August 2021
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
19. August 2021
Zuerst gepostet (Tatsächlich)
25. August 2021
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
25. August 2021
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
19. August 2021
Zuletzt verifiziert
1. Juli 2021
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 6077
- 4927 (PRIISA)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
NEIN
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Brustkrebs
-
Novartis PharmaceuticalsAbgeschlossenMetastasierter Brustkrebs (MBC) | Locally Advance Breast Cancer (LABC)Vereinigtes Königreich, Spanien
-
BioNTech SESeventh Framework ProgrammeAbgeschlossenBrustkrebs (Triple Negative Breast Cancer (TNBC))Schweden, Deutschland
-
Filipa Lynce, MDAstraZeneca; Daiichi Sankyo, Inc.RekrutierungBrustkrebs | HER2-positiver Brustkrebs | Invasiver Brustkrebs | Entzündlicher Brustkrebs Stadium III | HER2 Low Breast AdenokarzinomVereinigte Staaten